{
    "organizations": [],
    "uuid": "11bebe435e1d487fee8eeca40cd0fccef22ef0e1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-celyads-cyad-01-induced-complete-r/brief-celyads-cyad-01-induced-complete-remission-in-relapsed-refractory-aml-patient-idUSFWN1S40JN",
    "ord_in_thread": 0,
    "title": "BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27 (Reuters) - CELYAD SA:\n* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT\n* PATIENT ACHIEVED A COMPLETE MOLECULAR REMISSION AND REMAINS IN REMISSION 9 MONTHS POST STUDY ENROLLMENT\n* CYAD-01 WAS WELL TOLERATED WITH NO SIGNIFICANT TOXICITIES\n* DEMONSTRATED 1ST OBJECTIVE RESPONSE TO ANY CAR-T IN RELAPSED/REFRACTORY AML WITHOUT PRECONDITIONING CHEMOTHERAPY HIGHLIGHTS POTENTIAL OF CYAD-01 AS TREATMENT FOR AML Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-27T14:33:00.000+03:00",
    "crawled": "2018-04-28T12:25:39.048+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "celyad",
        "sa",
        "haematologica",
        "publishes",
        "celyad",
        "think",
        "study",
        "case",
        "report",
        "induced",
        "complete",
        "remission",
        "aml",
        "patient",
        "patient",
        "achieved",
        "complete",
        "molecular",
        "remission",
        "remains",
        "remission",
        "month",
        "post",
        "study",
        "enrollment",
        "well",
        "tolerated",
        "significant",
        "toxicity",
        "demonstrated",
        "1st",
        "objective",
        "response",
        "aml",
        "without",
        "preconditioning",
        "chemotherapy",
        "highlight",
        "potential",
        "treatment",
        "aml",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}